You are in: eMedicine Specialties > Pediatrics: General Medicine > Infectious Disease Human BitesArticle Last Updated: Dec 20, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Clifford Spanierman, MD, Consulting Staff, Departments of Emergency Medicine and Pediatrics, Lutheran General Hospital of Oak Brook, Advocate Health System Editors: Harold K Simon, MD, Director of Fellowship and Research, Associate Professor, Department of Pediatrics, Division of Pediatric Emergency Medicine, Emory University School of Medicine; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Wayne Wolfram, MD, MPH, Clinical Associate Professor, Departments of Pediatrics, Children's Hospital and University of Cincinnati; Paul D Petry, DO, FACOP, FAAP, Clinical Assistant Professor of Pediatrics, University of North Dakota, School of Medicine and Health Sciences; Consulting Staff, Altru Health System; Russell W Steele, MD, Professor and Vice Chairman, Department of Pediatrics, Head, Division of Infectious Diseases, Louisiana State University Health Sciences Center Author and Editor Disclosure Synonyms and related keywords: human bites, puncture wound, hand infection, wound infection, Staphylococcus, Streptococcus, Clostridium, fight wound, laceration, osteomyelitis, closed-fist bite wounds INTRODUCTIONBackgroundHuman bites are common in the pediatric age group. Bites may be inflicted during altercations, during play, or even by abusive adults. Bite wounds vary from superficial abrasions to severely disfiguring injuries. The most common complication of human bites is infection. Many concerned parents bring children (particularly younger children) with superficial bite wounds to medical personnel because of the fear of infectious disease transmission. PathophysiologyBacteria heavily colonize the human mouth. Oral flora contains many potentially pathogenic aerobic and anaerobic bacteria. Among these bacteria are Staphylococcus, Streptococcus, Clostridium, and fusiform-shaped species. Bite wounds can inoculate the affected tissue with these microorganisms. Bites cause varying amounts of tissue destruction. Tissue destruction from human bites tends to be less severe than that of dog bites. Nevertheless, human bites may be potentially disabling or life threatening. FrequencyUnited StatesEstimates vary regarding the frequency of human bites evaluated in US emergency departments (EDs). Some sources report an annual incidence of 250,000 human bites. This is well below the incidence of dog bites and is approximately half the incidence of cat bites. Mortality/Morbidity
Sex
Age
CLINICALHistory
Physical
Causes
DIFFERENTIALSChild Abuse & Neglect: Physical Abuse
|
| Drug Name | Amoxicillin and clavulanate (Augmentin) |
|---|---|
| Description | Combination antibiotic containing amoxicillin with a beta-lactamase inhibitor, which extends the antibiotic spectrum. Overall, the spectrum of this antibiotic provides the best prophylaxis against potential pathogens. In children, base dose on the amoxicillin content. Because of the different amoxicillin-clavulanic acid ratios in the 250-mg tablets (250/125) vs the 250-mg chewable tablets (250/62.5), do not use the 250 mg tablet until the child weighs >40 kg. |
| Adult Dose | 500-875 mg PO bid |
| Pediatric Dose | <3 months: Use the 125 mg/5 mL suspension and administer 30 mg/kg/d PO divided bid >3 months: If using the 200 mg/5 mL or 400 mg/5 mL suspension, administer 45 mg/kg/d PO q12h; if using the 125 mg/5 mL or 250 mg/5 mL suspension, administer 40 mg/kg/d PO q8h >40 kg: Administer as in adults |
| Contraindications | Documented hypersensitivity to penicillins; prior Augmentin-induced hepatic dysfunction |
| Interactions | Probenecid inhibits renal excretion of amoxicillin; coadministration with warfarin or heparin increases risk of bleeding |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in patients with liver dysfunction or cholestatic jaundice; pseudomembranous colitis has been associated with Augmentin use; common adverse effects include rash and gastrointestinal upset |
| Drug Name | Ampicillin and sulbactam (Unasyn) |
|---|---|
| Description | Similar in spectrum to Augmentin. Treatment of choice for infected human bites. Contains two-thirds ampicillin and one-third sulbactam. Pediatric doses based on the ampicillin component. |
| Adult Dose | 1.5 g (1 g ampicillin plus 0.5 g sulbactam) IV q6h |
| Pediatric Dose | 100-150 mg/kg/d (based on ampicillin component) IV divided q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid inhibits renal elimination; allopurinol decreases ampicillin effects and has additive effects on ampicillin rash; may decrease effects of PO contraceptives |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | May cause pseudomembranous colitis; appearance of rash should be evaluated carefully to differentiate a nonallergic ampicillin rash from a hypersensitivity reaction; adjust dose in renal insufficiency |
| Drug Name | Trimethoprim and sulfamethoxazole (Bactrim, Septra) |
|---|---|
| Description | Used in combination with clindamycin for prophylaxis or treatment in patients who are allergic to penicillin. Inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid. TMP blocks the production of tetrahydrofolic acid by inhibiting the enzyme dihydrofolate reductase; thus, this combination blocks 2 consecutive steps in the bacterial biosynthesis of essential nucleic acids and proteins. In vitro, bacterial resistance develops more slowly with this combination than with either drug alone. |
| Adult Dose | 1 double-strength tab (160 mg TMP/800 mg SMZ) PO q12h |
| Pediatric Dose | <2 months: Contraindicated >2 months: 5-10 mg/kg/d (based on TMP component) PO divided q12h |
| Contraindications | Documented hypersensitivity; megaloblastic anemia caused by folate deficiency; age <2 mo |
| Interactions | May increase PT of warfarin; monitor coagulation tests and adjust dosage as required; coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly patients; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Discontinue at first appearance of rash or sign of adverse reaction; obtain CBC counts frequently; discontinue therapy if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; prolonged IV infusions or high doses may cause bone marrow depression (if signs occur, give 5-15 mg/d leucovorin); caution in folate deficiency (eg, chronic alcoholism, elderly persons, patients receiving anticonvulsant therapy, malabsorption syndrome); hemolysis may occur in G-6-PD deficiency; patients with AIDS may not tolerate or respond to TMP-SMZ; caution in renal or hepatic impairment (perform urinalyses and renal function tests during therapy); give fluids to prevent crystalluria and stone formation |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Used for prophylaxis or treatment of the human bites in combination with TMP-SMX. Inhibits bacterial protein synthesis by its action at the bacterial ribosome. The antibiotic binds preferentially to the 50S ribosomal subunit and affects the process of peptide chain initiation. |
| Adult Dose | 150-450 mg PO q6-8h 1200-1800 mg IV divided bid/qid |
| Pediatric Dose | 10-30 mg/kg/d PO divided tid/qid 25-40 mg/kg/d IV divided q6-8h |
| Contraindications | Documented hypersensitivity; regional enteritis, ulcerative colitis, hepatic impairment, antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects of clindamycin; antidiarrheals may delay absorption of clindamycin |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis by allowing overgrowth of Clostridium difficile |
| Drug Name | Erythromycin (E.E.S., E-Mycin, Eryc, Erythrocin) |
|---|---|
| Description | Used for prophylaxis in penicillin-allergic patients. Macrolide antibiotic with a large spectrum of activity. Binds to the 50S ribosomal subunit of bacteria, which inhibits protein synthesis. |
| Adult Dose | 250-500 mg (base, stearate, or estolate) PO qid or 400-800 mg (ethylsuccinate) PO qid |
| Pediatric Dose | 30-50 mg/kg/d (base and ethylsuccinate) PO divided q6-8h |
| Contraindications | Documented hypersensitivity; hepatic impairment |
| Interactions | CYP 3A4 inhibitor, erythromycin decreases clearance of terfenadine, cisapride, and astemizole, which may result in serious cardiac arrhythmias; decreases clearance of cyclosporine, midazolam, phenytoin, triazolam theophylline, and carbamazepine; may potentiate anticoagulant effect of warfarin |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in liver disease; estolate formulation may cause cholestatic jaundice; GI adverse effects are common (give doses pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur |
Article Last Updated: Dec 20, 2007